Project Grant R01CA290201
Award Date
12/1/24
Completion Date
11/30/29
Dollars Obligated
$627K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Charleston, SC 29425, USA
Similar Awards
This Project Grant award of $102,324, provided by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), supports research at the Medical University of South Carolina (MUSC) to elucidate the impact of peroxisome biogenesis on adaptive immune responses, particularly within the tumor microenvironment and anti-tumor immunity. The overarching goal is to understand how enhancing peroxisome capacity in T cells can improve their persistence and mitigate exhaustion when exposed to...
The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), awarded a $563,233 Project Grant (CFDA 93.396 - Cancer Biology Research) to the Medical University of South Carolina. The 5-year grant, which commenced on April 1, 2025, supports research to investigate how the sphingosine kinase 2 (SPHK2)/sphingosine-1-phosphate (S1P) axis regulates the immunosuppressive function of myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment. The key objectives...
This Project Grant award of $445,996 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to investigate how mitigating oxidative stress at T cell telomeres can improve the function and efficacy of adoptive cell therapies against cancer. The research, conducted by the University of Pittsburgh, has two key objectives: Determine the mechanistic role of oxidative damage at telomeres on T cell function and how protecting telomeres with an antioxidant protein can...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will support research at the University of North Carolina at Chapel Hill to investigate how the tumor microenvironment impacts T cell metabolism and antitumor immunity. The $496,391 award, with a project period from December 2024 to November 2029, will fund experiments using genetic mouse models, patient tumor samples, and preclinical CAR-T cell models to determine if the enzyme acetyl-CoA...
The National Cancer Institute (NCI) awarded a $162,486 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the University of Pittsburgh. The project aims to investigate the functional consequences of high glucose culture on adoptive T cell therapies for cancer. Specifically, the research will (1) identify cellular proteins that are differentially O-GlcNAcylated under high glucose conditions and determine if inhibiting O-GlcNAcylation can restore T cell...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) in the amount of $121,857 aims to systematically investigate how anti-cancer drugs modulate T cells in the tumor microenvironment. The key objectives are to: Conduct in silico screening to identify anti-cancer drugs impacting T cell effector function, activation, stemness, and proliferation (Aim I). Perform single-cell CRISPR knockout screening to determine anti-cancer drug targets...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $108,512 to Emory University to conduct research on the role of the ICOS co-stimulatory molecule in improving the durability and persistence of anti-tumor T cells. The research aims to investigate how ICOS signaling induces resident memory phenotypes in T cells, and how incorporating ICOS into chimeric antigen receptor (CAR) T cells can enhance their anti-tumor efficacy in melanoma....
This $103,948 Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to the Sloan-Kettering Institute for Cancer Research supports research aimed at elucidating the mechanisms driving T-cell dysfunction within the tumor microenvironment. The research plan includes two main components: Predoctoral research (Aim 1) to investigate how local amino acid availability limits effector function in tumor-infiltrating T-cells, including profiling the...
This federal Project Grant award in the amount of $906,000.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant titled "Defining and Targeting Cancer Cell-Intrinsic Vulnerabilities in Renal Cell Carcinoma" will be performed by the Medical University of South Carolina (MUSC) from August 1, 2024 to July 31, 2027. Through this funding, MUSC will conduct innovative biomedical research to study novel therapies...
The National Cancer Institute (NCI) awarded a $159,540 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the University of North Carolina at Chapel Hill (UNC-CH). The grant supports research to characterize and overcome major histocompatibility complex class I (MHC-I)-mediated immune evasion in triple-negative breast cancer (TNBC). The proposed research aims to functionally and molecularly characterize MHC-I-low breast tumors, and evaluate combination...